AstraZeneca said it would sell the European rights to acid-reflux medicine Nexium to Grunenthal for an upfront $700 million and future sales-related payments of up to $90 million as it is not in the company's targeted therapy areas.

https://ift.tt/2DckFgk support@endlesssupplies.biz (Endless Supplies .Biz) October 30, 2018 at 04:02AM
No comments:
Post a Comment